Treatment of COVID-19-induced refractory status epilepticus by tocilizumab.

Autor: Kizilkilic EK; Department of Neurology, Cemil Taşcıoğlu City Hospital, Istanbul, Turkey., Unkun R; Department of Neurology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey., Uygunoglu U; Department of Neurology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey., Delil S; Department of Neurology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey., Ozkara C; Department of Neurology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
Jazyk: angličtina
Zdroj: European journal of neurology [Eur J Neurol] 2022 Sep; Vol. 29 (9), pp. 2861-2863. Date of Electronic Publication: 2022 Jun 22.
DOI: 10.1111/ene.15440
Abstrakt: Background and Purpose: COVID-19 is a novel infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in which neurological complications have been increasingly recognized. Acute symptomatic epileptic seizures and status epilepticus are frequently reported neurological complications associated with this infection. The nervous system damage caused by SARS-CoV-2 may be mediated by the immune system. Interleukin 6 (IL-6), an important component of the cytokine storm, is directly correlated with the severity of symptoms. Tocilizumab is an inhibitor of IL-6 receptors, which blocks IL-6-mediated signal transduction and is used in the treatment of COVID-19 and status epilepticus.
Case Report: A patient with the Unverricht-Lundborg disease is presented who had developed refractory recurrent status epilepticus during COVID-19 infection, which was finally controlled by treatment with tocilizumab.
Discussion: Tocilizumab, an IL-6 inhibitor, may be considered as a treatment option in patients with status epilepticus and refractory seizures.
(© 2022 European Academy of Neurology.)
Databáze: MEDLINE
Externí odkaz: